This post was originally published on this site
Original post: Newswise - Drug and Drug Abuse Axi-cel CAR T cell therapy shows enhanced responses and continued benefit for high-risk lymphoma patients
Three clinical studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated enhanced responses for patients with high-risk lymphoma treated with axicabtagene ciloleucel (axi-cel) chimeric antigen receptor (CAR) T cell therapy. These results were reported at the 2021 American Society of Hematology (ASH) Annual Meeting.